AMENDMENT NO. 9 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 14th, 2020 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This Amendment No. 9 to the Collaboration and License Agreement (“Amendment”) is made and entered into by and between Kyowa Kirin Co., Ltd. (formerly, Kyowa Hakko Kirin Co., Ltd.), a company organized and existing under the laws of Japan, with an address at 1-9-2 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“KKC”) and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni Court, Novato, California 94949, USA (“UGNX”).
WOBURN MCB II, LLC Lease To ULTRAGENYX PHARMACEUTICAL INC.Office Lease • February 14th, 2020 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Massachusetts
THE SUBMISSION OF THIS LEASE FOR EXAMINATION, REVIEW, NEGOTIATION AND/OR SIGNATURE SHALL NOT CONSTITUTE AN OFFER OR AN OPTION TO LEASE OR A RESERVATION OF THE PREMISES AND IS SUBJECT TO WITHDRAWAL OR MODIFICATION AT ANY TIME BY EITHER PARTY. THIS LEASE SHALL BECOME EFFECTIVE AND BINDING ONLY IF AND WHEN IT SHALL BE EXECUTED AND DELIVERED BY BOTH LANDLORD AND TENANT.
COMMERCIAL LEASECommercial Lease • February 14th, 2020 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
Royalty Purchase Agreement By and Between Ultragenyx Pharmaceutical Inc. and RPI Finance Trust Dated as of December 17, 2019Royalty Purchase Agreement • February 14th, 2020 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This ROYALTY PURCHASE AGREEMENT, dated as of December 17, 2019 (this “Agreement”), is made and entered into by and between Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Seller”), on the one hand, and RPI Finance Trust, a Delaware statutory trust (the “Buyer”), on the other hand.
